6-羟基黄体酮 | 604-20-6

• 物质功能分类: 医药中间体 - 原料药中间体
• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 中文名称: 6-羟基黄体酮
• 英文名称: 6ζ-hydroxypregn-4-ene-3,20-dione
• 英文别名: 6-hydroxyprogesterone；6-Hydroxypregn-4-ene-3,20-dione；(8S,9S,10R,13S,14S,17S)-17-acetyl-6-hydroxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one
• CAS: 604-20-6
• 化学式: C₂₁H₃₀O₃
• 分子量: 330.467
• InChiKey: PWCLWZOSAFOXFL-UHPWKVKZSA-N

物化性质

• 熔点：
  >155°C (dec.)
• 沸点：
  490.8±45.0 °C(Predicted)
• 密度：
  1.15±0.1 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿（轻微，超声），乙酸乙酯（轻微），甲醇（轻微）

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  24
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.81
• 拓扑面积：
  54.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  孕烯醇酮 以 水 为溶剂， 反应 192.0h， 生成 黄体酮 、 6-羰基黄体酮 、 6-羟基黄体酮
  参考文献：
  名称：

  Stereospecific Oxidation of 3β-Hydroxysteroids by Persolvent Fermentation withPseudomonassp. ST-200

  摘要：

  从腐殖土中分离得到的Pseudomonas sp. 菌株ST-200能有效氧化溶解于有机溶剂中的胆固醇，但不能氧化悬浮于生长介质中的胆固醇。该菌株不吸收胆固醇，但能氧化多种溶解于有机溶剂的5α-或5-烯甾醇。首先，将3β-OH基团氧化为酮基，而3α-OH基团几乎不被氧化。接着，5-烯甾体的C-6位进行羟基化，5-烯甾体的双键从Δ5转移到Δ4。随后，6-OH基团被氧化为酮基。利用ST-200进行溶剂发酵可提供一种有效、便捷且具有立体选择性的方法，用于甾体化合物C-3和C-6位的氧化。

  DOI：

  10.1271/bbb.60.1146

文献信息

• Targeted moieties for use in bleach catalysts
  申请人：Unilever Home & Personal Care USA, Division of Conopco, Inc.

  公开号：US20020049146A1

  公开（公告）日：2002-04-25

  There is provided a targeted bleaching composition comprising an organic substance which forms a complex with a transition metal, the complex catalyzing bleaching of a substrate by a precursor selected from atmospheric oxygen and/or a peroxyl species. The complex is bound to a recognizing portion having a high binding affinity for stains present on fabrics.

  提供了一种有针对性的漂白组合物，包括一种有机物质，该有机物质与过渡金属形成配合物，该配合物通过来自大气氧气和/或过氧基物质的前体催化基质的漂白。该配合物与具有高亲和力的识别部分结合，以便于对织物上的污渍进行识别。
• Novel 6-oxygenated-3,20-dioxo-pregnane derivatives, process for the preparation thereof, and pharmaceutical compositions containing them
  申请人：Technobiotic Ltd.

  公开号：EP0001864A1

  公开（公告）日：1979-05-16

  Disclosed are novel 6-oxygenated-3,20-dioxo-pregnane derivatives of the general formula I and specified 1,2-dihydroderivatives thereof. D is ,wherein Z represents specified acylgroups. The other substituents of formula I include those commonly met in known corticosteroids. The novel compounds may be prepared by methods known per se. The 6-acyloxy compounds of formula I are preferably prepared by subjecting a corresponding 6-oxo-compound of formula II, as herein defined, to esterification conditions. The 6-oxo-compounds of formula I are preferably prepared by oxidation of the corresponding 6-hydroxy-6,7-dihydro compounds. The novel compounds exhibit anti-inflammatory activity and are therefore useful in the treatment and control of inflammatory conditions.

  公开了通式 I 的新型 6-氧代-3,20-二氧代孕甾烷衍生物 及其特定的 1,2-二氢衍生物。D 是 其中 Z 代表特定的酰基。 式 I 的其它取代基包括已知皮质类固醇中常见的取代基。 新型化合物可通过本身已知的方法制备。式 I 的 6-乙酰氧基化合物优选通过将相应的式 II 的 6-氧代化合物（如本文所定义）置于酯化条件下制备。式 I 的 6-氧代化合物优选通过氧化相应的 6-羟基-6,7-二氢 化合物制备。新型化合物具有抗炎活性，因此可用于治疗和控制炎症。
• A process for the selective conversion of 20-methylpregna-3,5,20(21)-triene-3,21-diol-diacetate to 3-oxo-20-methyl-pregna-4,20(21)-diene-21-yl-acetate
  申请人：HENKEL CORPORATION (a Delaware corp.)

  公开号：EP0004430A2

  公开（公告）日：1979-10-03

  The present invention relates to the selective conversion of 20-methylpregna-3,5,20(21)- triene-3,21-diol-diacetate to 3-oxo-20-methylpregna-4,20(21)- diene-21-yl-acetate by the use of a halogenated solvent and a halogenated acid. This process provides improved recovery of 3-oxo-20-methylpregna-4,20(21)- diene-21-yl acetate which is a useful intermediate in the preparation of progesterone.

  本发明涉及使用卤化溶剂和卤化酸将 20-甲基孕甾-3,5,20(21)-三烯-3,21-二醇二乙酸酯选择性转化为 3-氧代-20-甲基孕甾-4,20(21)-二烯-21-基乙酸酯。该工艺提高了 3-氧代-20-甲基孕甾-4,20(21)-二烯-21-基乙酸酯的回收率，该乙酸酯是制备黄体酮的有用中间体。
• Methods of measuring human cytochrome P450 (CYP2C8/9)
  申请人：Merck & Co., Inc.

  公开号：EP2000532A1

  公开（公告）日：2008-12-10

  Monoclonal antibodies (MAbs) have been developed to human cytochrome P450 2C8/9 (CYP2C8/9) by the fusion of myeloma tumour cells with isolated B-lymphocytes from spleens of mice immunised with baculovirus-expressed human CYP2C9; the MAbs for CYP2C9 are very powerful inhibitors of CYP2C8/9 activity and stray binders of the enzymes on Western blot and exhibit no cross-reactivity towards any of the other P450 subfamily members; based on these features the MAbs are useful tools for measuring CYP2C8/9 and assessing the role of CY2C8/9 in the metabolism of various compounds.

  通过将骨髓瘤肿瘤细胞与用表达人 CYP2C9 的杆状病毒免疫的小鼠脾脏中分离出的 B 淋巴细胞融合，开发出了针对人细胞色素 P450 2C8/9（CYP2C8/9）的单克隆抗体（MAbs）；CYP2C9 的 MAbs 是 CYP2C8/9 活性的强力抑制剂，在 Western 印迹上是酶的杂散结合剂，对其他 P450 亚家族成员没有交叉反应；基于这些特点，MAbs 是测量 CYP2C8/9 和评估 CY2C8/9 在各种化合物代谢中的作用的有用工具。
• Pharmaceutical Emulsion Compositions Comprising Progestogen
  申请人：Besins Healthcare Luxembourg SARL

  公开号：EP2801353A1

  公开（公告）日：2014-11-12

  The invention relates to a sterile, ready-to-use, pharmaceutical oil-in water emulsion composition for parenteral administration comprising: 0.015 to 1.2% wt./vol. of progestogen; 0.5-30% wt./vol.oil, wherein the oil comprises at least 85% wt.wt. triglyceride; 0.0425-12.5% wt./vol phospholipid; 61.4-99.4% wt./vol. aqueous medium; wherein the phospholipid is present in an amount of 6.8% - 43% of the oil (wt./wt.), and wherein the progestogen is present in an amount greater than or equal to 2.1wt% of the oil, preferably greater than or equal to 2.2wt% of the oil. The invention further relates to the use of the aforementioned composition in therapeutic or prophylactic treatment, said treatment comprising intravenous administration of the pharmaceutical composition.

  本发明涉及一种无菌、即开即用、用于肠外给药的水包油药用乳液组合物，该组合物包括0.015-1.2%重量/体积的孕激素；0.5-30%重量/体积的油，其中油包括至少85%重量/体积的甘油三酯；0.0425-12.5%重量/体积的磷脂；61.4-99.4%重量/体积的水介质；其中磷脂的含量为油（重量/体积）的6.8% - 43% (重量/体积)，其中孕激素的含量大于或等于油的 2.1wt%，优选大于或等于油的 2.2wt%。本发明进一步涉及上述组合物在治疗或预防性治疗中的用途，所述治疗包括静脉注射该药物组合物。